These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17827843)

  • 21. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valsartan and recurrent atrial fibrillation.
    Smit MD; Van Gelder IC
    N Engl J Med; 2009 Jul; 361(5):532; author reply 533. PubMed ID: 19641214
    [No Abstract]   [Full Text] [Related]  

  • 23. Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Cheung BM
    Hong Kong Med J; 2004 Oct; 10(5):359. PubMed ID: 15479968
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of valsartan on the incidence of diabetes.
    Luan FL
    N Engl J Med; 2010 Aug; 363(8):792; author reply 792-3. PubMed ID: 20718670
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valsartan and recurrent atrial fibrillation.
    Tomoda H
    N Engl J Med; 2009 Jul; 361(5):532-3; author reply 533. PubMed ID: 19645082
    [No Abstract]   [Full Text] [Related]  

  • 27. [Refractory hypotension during anesthesia in a patient treated with angiotensin receptor blockers].
    Vaquero Roncero LM; Julián González R; Muriel Villoria C
    Rev Esp Anestesiol Reanim; 2004; 51(6):338-41. PubMed ID: 15303535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging].
    Inoue M; Fujii S; Taisei M; Furumoto T; Kaga S; Komatsu H; Goto K; Komuro K; Yamada S; Onozuka H; Kitabatake A; Tsutsui H
    J Cardiol; 2006 Jan; 47(1):9-14. PubMed ID: 16475468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report].
    Hiroki J; Fukumoto Y; Shimokawa H; Hirooka Y; Takeshita A
    J Cardiol; 2004 Oct; 44(4):161-4. PubMed ID: 15532247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combination therapy in contemporary strategy of treatment of arterial hypertension. Review of data on efficacy and safety of fixed combination valsartan and hydrochlorothiazide].
    Kobalava ZhD; Villeval'de SV
    Kardiologiia; 2006; 46(10):87-92. PubMed ID: 17171858
    [No Abstract]   [Full Text] [Related]  

  • 31. Valsartan prevents neointimal hyperplasia after carotid artery stenting by suppressing endothelial cell injuries.
    Suzuki H; Sano T; Umeda Y; Yamamoto A; Toma N; Sakaida H; Taki W
    Neurol Res; 2015 Jan; 37(1):35-42. PubMed ID: 24938321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of unstable angina pectoris associated with an active phase of polymyositis].
    Yasu T; Nonogi H; Oshima S; Daikoku S; Haze K
    Kokyu To Junkan; 1992 May; 40(5):491-4. PubMed ID: 1589649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.
    Yamamoto T; Sata M; Fukuda D; Takamoto S
    Basic Res Cardiol; 2005 Jan; 100(1):84-91. PubMed ID: 15490202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
    Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
    Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina.
    Hirai N; Kawano H; Yasue H; Shimomura H; Miyamoto S; Soejima H; Kajiwara I; Sakamoto T; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
    Circulation; 2003 Sep; 108(12):1446-50. PubMed ID: 12952843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valsartan for prevention of recurrent atrial fibrillation.
    ; Disertori M; Latini R; Barlera S; Franzosi MG; Staszewsky L; Maggioni AP; Lucci D; Di Pasquale G; Tognoni G
    N Engl J Med; 2009 Apr; 360(16):1606-17. PubMed ID: 19369667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.